Skip to main content
News and Events banner photo

News & Events
Stay Informed with Industry Insights and Follow Our Progress

Scientist in background holding filled vial in foreground

Filter

Company NewsRAG-17

Ractigen Therapeutics Receives IND Approval from China’s NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients

JIANGSU, CHINA (May 15, 2024) – Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing…
May 15, 2024
Company NewsRAG-01

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

JIANGSU, China, April 26, 2024 — Ractigen Therapeutics, a leader in the development of small…
April 26, 2024
Company NewsRAG-01

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…
April 3, 2024
Company News

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

Suzhou, China – January 29, 2024 – Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the…
January 29, 2024
Company NewsRAG-01

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

JIANGSU, China, Dec. 06, 2023 — Ractigen Therapeutics, a leader in the field of small…
December 6, 2023
Company News

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Findings support saRNA as a therapeutic strategy to compensate dystrophin’s function by upregulating UTRN expression…
November 2, 2023